The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
Open accessAbstract
Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients. Using the fixed and random effects models, pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were calculated for pathological complete response (pCR, defined as ypT0/is pN0), event-free survival (EFS), overall survival (OS) and grade 3 and 4 adverse events (AEs: neutropenia, anemia, thrombocytopenia and neuropathy). Results: Nine RCTs (N = 2109) were included. Overall, platinum-based neoadjuvant chemotherapy significantly increased pCR rate from 37.0% to 52.1% (OR 1.96, 95% CI 1.46-2.62, P < 0.001). Platinum-based neoadjuvant chemotherapy remained significantly associated with increased pCR rate also after restricting the analysis to the three RCTs (N = 611) that used the same standard regimen in both groups of weekly paclitaxel (with or without carboplatin) followed by anthracycline and cyclophosphamide (OR 2.53, 95% CI 1.37-4.66, P = 0.003). Conversely, among the 96 BRCA-mutated patients included in two RCTs, the addition of carboplatin was not associated with significantly increased pCR rate (OR 1.17, 95% CI 0.51-2.67, P = 0.711). Two RCTs (N = 748) reported survival outcomes: no significant difference in EFS (HR 0.72, 95% CI 0.49-1.06, P = 0.094) and OS (HR 0.86, 95% CI 0.46-1.63, P = 0.651) was observed. A significant higher risk of grade 3 and 4 hematological AEs, with no increased risk of grade 3 and 4 neuropathy was observed with platinum-based neoadjuvant chemotherapy. Conclusion: In TNBC patients, platinum-based neoadjuvant chemotherapy is associated with significantly increased pCR rates at the cost of worse hematological toxicities. Platinum-based neoadjuvant chemotherapy may be considered an option in TNBC patients. PROSPERO registration number: CRD42018080042.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 5×
“In the presence of significant heterogeneity among the trials, the more appropriate method of DerSimonian and Laird was computed for the pooled estimate of the ORs using the random effects model [16].”
MethodInfluentialLehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267 · cited 1×
“The likelihood of publication bias was assessed by visual inspection of funnel plot for study size against treatment effect [18] and with Harbords’ asymmetry test [19].”
MethodThe Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Higgins, J., Thompson, S., Deeks, J., & Altman, D. (2002) · Journal of Health Services Research & Policy · doi:10.1258/1355819021927674 · Cited by 755
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0044 · Cited by 529
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., Jakubowicz, J., Cybulski, C., Wisniowski, R., Godlewski, D., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3100-x · Cited by 269
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
Paluch-Shimon, S., Pagani, O., Partridge, A. H., Abulkhair, O., Cardoso, M.-J., Dent, R. A., Gelmon, K., Gentilini, O., Harbeck, N., Margulies, A., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.07.017 · Cited by 247
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., Elia, M., Connor, C. S., McGinness, M. K., Mammen, J. M. W., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2980-0 · Cited by 201
Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx036 · Cited by 151
Alba, E., Chacón, J. I., Lluch, A. M., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Seguí, M. Á., Ribelles, N., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2100-y · Cited by 147
Gluz, O., Nitz, U. A., Liedtke, C., Christgen, M., Grischke, E., Forstbauer, H., Braun, M., Warm, M. R., Hackmann, J., Uleer, C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx258 · Cited by 133
Zhang, P., Yin, Y., Mo, H., Zhang, B., Wang, X., Li, Q., Yuan, P., Wang, J., Zheng, S., Cai, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10607 · Cited by 91
Sikov, W. M., Berry, D., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Somlo, G., Port, E., Qamar, R., Sturtz, K. B., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-05 · Cited by 85
Ando, M., Yamauchi, H., Aogi, K., Shimizu, S., Iwata, H., Masuda, N., Yamamoto, N., Inoue, K., Ohono, S., Kuroi, K., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2947-1 · Cited by 82
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer
Harbeck, N., & Gluz, O. (2017) · The Breast · doi:10.1016/j.breast.2017.06.038 · Cited by 78
Birkbak, N. J., Li, Y., Pathania, S., Greene-Colozzi, A., Dreze, M., Bowman-Colin, C., Sztupinszki, Z. M., Krzystanek, M., Dióssy, M., Tung, N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy049 · Cited by 59
Signatures of DNA-Repair Deficiencies in Breast Cancer
Turner, N. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmcibr1710161 · Cited by 26
Cited by
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,040
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Metadata
- Authors
- Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 29
- Issue
- 7
- Pages
- 1497-1508
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2807418950
- Cited by
- 468
- References
- 42
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.